Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08634404 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PF-08634404 + chemotherapy is an investigational combination therapy being developed by Pfizer for the treatment of advanced gastroesophageal cancers, including gastric, gastroesophageal junction, and esophageal adenocarcinomas. The regimen consists of PF-08634404, a bispecific monoclonal antibody, and standard-of-care chemotherapy. PF-08634404 simultaneously targets the Programmed Cell Death Protein 1 (PD-1) immune checkpoint and the Vascular Endothelial Growth Factor (VEGF) pathway. By inhibiting PD-1, the drug enhances T-cell mediated anti-tumor immune responses, while VEGF inhibition suppresses tumor-associated angiogenesis and may improve the delivery of chemotherapy by normalizing tumor vasculature. This combination is currently being evaluated in Phase 3 clinical trials as a first-line treatment for several solid tumors.
- Other names
- PF-08634404 plus chemotherapyPF08634404 plus chemotherapyPF 08634404 plus chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on PF-08634404 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08634404 + chemotherapy.